Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 09 - 28 save search
JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101
Published: 2021-09-28 (Crawled : 18:00) - janone.com
JAN | $4.75 5.21% 4.95% 190K
|
Industrial Services
|
| O: -0.43%
H: 12.81%
C: 8.01%
fda phase 2 communication communications drug phase 2b trial designation
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
Published: 2021-09-28 (Crawled : 14:15) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -0.59%
H: 0.3%
C: -2.44%
stroke phase 2 neurological life science
Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer
Published: 2021-09-28 (Crawled : 14:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 2.8%
H: 0.34%
C: -10.23%
partnership phase 2 lung cancer collaboration cancer trial enroll
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Published: 2021-09-28 (Crawled : 14:00) - biospace.com/
MGNX | $15.7 -3.27% -3.38% 520K
|
Health Technology
|
| O: -1.31%
H: 2.55%
C: 1.03%
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: 5.74%
H: 1.23%
C: -6.32%
phase 2 solid tumors china trial
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
Published: 2021-09-28 (Crawled : 13:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -1.41%
H: 1.27%
C: 0.74%
phase 2 positive cancer colorectal cancer trial her2+ enroll her2- her2
Arrowhead Earns $10 Million Phase 1 Milestone Payment
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: -6.56%
phase 1 phase 2 phase 3 milestone
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
Published: 2021-09-28 (Crawled : 12:00) - globenewswire.com
FWBI | $3.04 -2.56% -2.63% 37K
|
Manufacturing
|
| O: 0.59%
H: 0.01%
C: -7.02%
phase 2 biopharma phase 2b trial
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
ALT | $7.095 -6.28% -6.69% 2.2M
|
Commercial Services
|
| O: -28.7%
H: 39.15%
C: 36.75%
positive results phase 1 positive results trial obesity phase 2 phase 3
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
Published: 2021-09-28 (Crawled : 07:00) - globenewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.15%
H: 0.06%
C: -0.6%
phase 1 positive results vaccine phase 2 phase 3
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
Published: 2021-09-28 (Crawled : 06:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
disease phase 2 positive phase 2 results results vaccine response
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.